Washington, DC 20006-5349
HELPLINE
Today, the Meso Foundation wrote a letter to the acting administrator of the EPA urging the agency to account for legacy asbestos when evaluating asbestos risk and the magnitude of the asbestos problem. This letter came as a response to the EPA’s decision to exclude legacy uses of asbestos in its problem formulation. This issue is separate from the recently publicized ‘significant new use rule.’ You can read more here.
EPA_Legacy_Comment_MesoFoundation
CAR-T (Chimeric antigen receptor) cell therapy is a type of immunotherapy that uses a patient’s T cells to attack cancer cells. T cells are white
For patients with MPM (Malignant Pleural Mesothelioma), the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) as a first-line treatment when combined with
Mesothelioma has often been classified as a cancer that only affects older people, as the average age of diagnosis for pleural is 72 and peritoneal
Get the latest information about mesothelioma, clinical trials, patient stories, community events, and much more!
